Prosecution Insights

Browse Companies Examiners Firms Draft Your Response

Last updated: August 18, 2026

Examiner: DUFFY, PATRICIA ANN

Tech Center 1600 • Art Units: 1644 1645

This examiner grants 53% of resolved cases

Performance Statistics

52.7%

Allow Rate

-7.3% vs TC avg

619

Total Applications

+34.2%

Interview Lift

1329

Avg Prosecution Days

Based on 569 resolved cases, 2023–2026

Rejection Statute Breakdown

7.5%

§101 Eligibility

20.4%

§102 Novelty

28.1%

§103 Obviousness

39.9%

§112 Clarity

Currently Pending Office Actions

App #	Title	Status	Assignee
17350898	IL-10-CONTAINING VACCINES AND USES THEREOF	Non-Final OA	The Regents of the University of California
18684437	PAENIBACILLUS STRAINS PRODUCING LOW AMOUNTS OF EXOPOLYSACCARIDES	Non-Final OA	BASF SE
18685422	DEVELOPMENT OF SYNTHETIC PSEUDAMINIC ACID-BASED ANTIBACTERIAL VACCINES AGAINST ACINETOBACTER BAUMANNII	Non-Final OA	City University of Hong Kong
18506636	COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING HUMAN CHLAMYDIAL INFECTIONS AND DISEASES USING ATTENUATED ANIMAL CHLAMYDIA	Non-Final OA	Board of Regents, The University of Texas System
18318062	ENDOLYSOSOMAL TARGETING CONJUGATES FOR IMPROVED DELIVERY OF CARGO MOLECULES TO THE ENDOLYSOSOMAL COMPARTMENT OF TARGET CELLS	Non-Final OA	Board of Regents of the University of Texas System
18718636	VACCINE	Non-Final OA	GLAXOSMITHKLINE BIOLOGICALS SA
18686089	Shigella Vaccine	Non-Final OA	GLAXOSMITHKLINE BIOLOGICALS SA
18256749	Hyper-Blebbing Bacteria	Non-Final OA	GLAXOSMITHKLINE BIOLOGICALS SA

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy